Curis Inc（CRIS）の株式分析CRISCuris Inc

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Curis Inc is a good buy right now due to its low current price of $1.49, which is significantly below the analyst price target of $43, indicating a potential upside of over 2800%. Additionally, the stock has a forward P/E ratio of 0, suggesting it is undervalued compared to future earnings potential. However, investors should be cautious of the significant net loss of $24.2 million reported for Q1 2026, which poses a risk to financial stability.

4 analysts cover CRIS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.